Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: A systematic review and meta-analysis

International Journal of Gynecological Cancer

Volumn 24, Issue 7, 2014, Pages 1222-1231

  Macedo, Ana Cristina Lacerda ^a   Da Rosa, Maria Inês ^a   Lumertz, Suéli ^a   Medeiros, Lidia Rosi ^b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Diagnostic systematic review; HE4; Human epididymis protein 4; Meta analysis; Ovarian cancer

Indexed keywords

PROTEIN; WFDC2 PROTEIN, HUMAN;

BLOOD; CYSTADENOFIBROMA; FEMALE; HUMAN; META ANALYSIS; METABOLISM; OVARIAN NEOPLASMS; PREDICTIVE VALUE; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

CYSTADENOFIBROMA; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84906853917     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000192     Document Type: Article

References (50)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212. doi: 10.3322/caac.20121.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-80. doi: 10.3322/caac.20107.
3. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40:1213-1223. doi: 10.1016/j.humpath.2009.04.017.
4. Badgwell D, Bast RC. Early detection of ovarian cancer. Disease Markers. 2007;23:397-410.
5. Medeiros LR, Rosa DD, Da Rosa MI, et al. Accuracy of CA125 in the diagnosis of the ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99-105. doi: 10.1016/j.ejogrb.2008.08.011.
6. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267-277.
7. Kirchhoff CI, Habben, Iveli R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biology of Reproduction. 1991;45:350-357.
8. Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Advances in Experimental Medicine and Biology. 2008;622:15-21. doi: 10.1007/978-0-387-68969-2-2.
9. Drapkin R, Von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-2169.
10. Scholler N, Crawford M, A. Sato A, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006;12:2117-2124.
11. Whiting PF, Weswood ME, Rutjes AW, et al. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9.
12. Smidt N, Deeks J, Bossuy P, et al. Guide to the contents of a Cochrane review and protocol. Cochrane Handbook for Systematic Review of Systematic review of Diagnostic Test Accuracy: Cochrane Colaboration. 2010 Avaliable in: 08/06/2013.
13. Schlesselman JJ, Stolley PD. Case control studies. Design, conduct, analysis. New York: Oxford University Press; 1982:174-177.
14. Deeks JJ. Systematic reviews of evaluation of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London, England: BMJ Publishing; 2001:248-282.
15. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data analytic approaches and some considerations. Sta Med. 1993;12:1293-1316.
16. Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol. 2006;187:271-281.
17. Reitsma JB, Glas AS, Rutjes A W S, et al. Bivariate analysis of sensitivity and specificity produce informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982-990.
18. Review Manager (RevMan) [Computer program] (2008). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration.
19. Chang X, Ye X, Dong L, et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011;21:852-858.
20. Escudero JM, Auge JM, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534-1544. doi: 10.1373/clinchem.2010.157073.
21. Li K, Yang Y, Li-zhen H, et al. Significance of combined determination of serum HE4 CA125 level and T lymphocyte subgroups in peripheral blood in early diagnosis of ovarian cancer. Chin J Biologicals. 2012;25:99-101.
22. Lenhard M, Stieber P, Hertlein L, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49:2081-2088. doi: 10.1515/CCLM.2011.709.
23. Liu YN, Ye X, Cheng HY, et al. Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan Ke Za Zhi. 2010;45:363-366.
24. Modares-Gilani M, Ghaemmaghami F, Mousavi A, et al. Simultaneous measurement of two serum markers (CA-125 and HE-4) while diagnosing malignant ovarian epithelial tumors. Pak J Med Sci. 2011;4:858-861.
25. Montagnana M, Lippi G, Ruzzenente O, et al. The Utility of Serum Human Epididymis Protein 4 (HE4) in Patients With a Pelvic Mass. J Clin Lab Anal. 2009;23:331-335. doi: 10.1002/jcla.20340.
26. Ruggeri G, Bandiera E, Zanotti L, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011;412:1447-1453. doi: 10.1016/j.cca.2011.04.028.
27. Molina R, Escudero JM, Augé JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32:1087-1095. doi: 10.1007/s13277-011-0204-3.
28. Ferraro S, Braga F, Lanzoni M, et al. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273-281. doi: 10.1136/jclinpath-2012-201031.
29. Lin JY, Qin JB, Li XY, et al. Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:5427-5432.
30. Wu L, Dai ZY, Qian YH, et al. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012;22:1106-1112. doi: 10.1097/IGC.0b013e318263efa2.
31. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013; doi: 10.1016/j.ejogrb.2012.10.036Mar;167(1):81-5.
32. Altman D. Relation between two continuous variables. In: Altman D, ed. Practical statistics for medical research. 9th ed. London, England: Chapman; 1999:277-299.
33. Sutton AJ, Abrams KR, Jones DR, et al. Random effects methods for combining study estimates. In: Sutton AJ, Abrams KR, Jones DR, et al, eds. Methods for meta-analysis in medical research. 1st ed. Chichester, England: John Wiley; 2000:73-86.
34. Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010;11:111-116.
35. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378-383.
36. Anton C, Carvalho FM, Oliveira EI, et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics. 2012;67:437-441.
37. Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? [abstracts]. Arch Gynecol Obstet. 2013; doi: 10.1007/s00404-013-2722-2.
38. Baba DU, Ugur M, Gungor T, et al. Clinical Importance Of Human Epidydimis Protein-4 (He4) In Predicting Malignancy Potentials Of Adnexial Masses. In: European Society of Gynecologic Oncology (ESGO 2011); 2011 Nov. 15; Milan; 2011. 6-6.
39. Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496-2506.
40. Chan KK, Chen CA, Nam JH, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239-244. doi: 10.1016/j.ygyno. 2012.09.034.
41. Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4:365-374. doi: 10.1158/1940-6207. CAPR-10-0195.
42. Dong L, Chang XH, Ye X, et al. The values of serum human epididymis secretory protein 4 and CA (125) assay in the diagnosis of ovarian malignancy. Zhonghua Fu Chan Ke Za Zhi. 2008;43:931-936.
43. Franchi D, Sandri M, Boveri S, et al. Ultrasound imaging compared to a multivariate predictive algorithm combining HE4 and CA 125 (ROMA) in the pre-operative assessment of adnexal masses. Ultrasound in Obstet Gynecol. 2011;38:1-55.
44. Freydanck MK, Laubender RP, Rack B, et al. Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses. Anticancer Res. 2012;32:2003-2008.
45. Granatova J, Boiecka K, Tma J, et al. He4: A novel tumor marker in differential diagnostics of ovarian cancer. In: Clinical Chemistry and Laboratory 2011 49 SUPPL. 1 (S240).
46. Guorui L, Yili W, Qi L, et al. Combined detection of serum CA125 and HE4 used for ovarian cancer diagnosis and differential diagnosis [abstract]. Chin J Clin Lab Sci. 2010.
47. Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374-382. doi: 10.1016/j.ygyno. 2008.04.041.
48. Hamed EO, Ahmed H, Sedeek OB, et al. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. [abstract]. Diagn Pathol. 2013;23; 8:11. doi: 10.1186/1746-1596-8-11.
49. He G, Holcroft CA, Beauchamp MC, et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Can. 2012;34:567-574.
50. Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121:487-491. doi: 10.1016/j.ygyno. 2011.02.022.